Sensitivity, specificity of 68Ga-PSMA PET in advanced prostate cancer: A systematic review and meta-analysis

Perera, María; Papa, Nathan; Christidis, Daniel; Wetherell, David; Hofman, M.; Murphy, Declan; Bolton, Damien; Lawrentschuk, Nathan

doi:10.1016/s1569-9056(16)30371-2

Cited by 9 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results of 68 Ga-PSMA PET/CT are different from those of a previously published meta-analysis performed by Perera et al [15]. In this article, they enrolled 16 articles with 1,309 patients, obtaining a pooled sensitivity and specificity of 0.86 and 0.86 for 68 Ga-PSMA PET/CT, respectively.…”

Section: Discussioncontrasting

confidence: 99%

“…Despite the similar result of AUC, we are not sur-prised by the difference between the two meta-analysis, because the different inclusion criteria resulted in the different pooled data. Specifically, in the patient selection, we only enrolled the preoperative patients without hormone therapy, however, Perera et al [15] included a result of mixed staging patients including primary staging and secondary staging patients with BCR. With regard to the patients with BCR, several previous articles revealed a high sensitivity of LNMs detection, ranging from 77.9% to 98.8% [38][39][40].…”

Section: Discussionmentioning

confidence: 99%

“…Perera et al [15] have previously performed a systematic review and meta-analysis to identify the sensitivity and specificity in advanced prostate cancer, indicating its high level of accuracy as a predictor. However, no relevant systematical review and metaanalysis over the comparison between 68 Ga-PSMA-PET and the conventional imaging modalities has been yet published.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Xu²,

Wang

et al. 2020

World J Mens Health

View full text Add to dashboard Cite

Purpose: To compare the diagnostic efficiency of 68 Gallium labelled prostate-specific membrane antigen positron emission tomography (68 Ga-PSMA PET) and magnetic resonance imaging (MRI) for staging the lymph node metastases (LNMs) in the prostate cancer. Materials and Methods: A broad search of scientific databases including PubMed, EMBASE, Web of Science, Cochrane Database, and Chinese Biomedicine Literature Database (updated prior to November 1st, 2018) was conducted systematically by two reviewers. In this paper, we evaluated the methodological quality of each included article independently and performed a systematic review and meta-analysis to reveal the summary of the diagnostic performance of 68 Ga-PSMA PET and MRI in properly identifying LNMs of intermediate-and/or high-risk prostate cancer. Results: Thirteen eligible articles comprising 1,597 patients were included. For LNMs detection, the pooled sensitivity and specificity of 68 Ga-PSMA PET were 0.65 (95% confidence interval [CI]: 0.49-0.79) and 0.94 (95% CI: 0.88-0.97), respectively, while the corresponding values of MRI were 0.41 (95% CI: 0.26-0.57) and 0.92 (95% CI: 0.86-0.95). The area under the symmetric receiver-operating characteristic (SROC) curve for 68 Ga-PSMA PET and MRI were 0.92 and 0.83, respectively. Conclusions: In intermediate-or high-risk pre-treatment prostate cancer, 68 Ga-PSMA PET had a higher sensitivity and a slightly different specificity in probing the LNMs when comparing with MRI. Moreover, the area under the SROC curve indicated that 68 Ga-PSMA PET was a more effective weapon for predicting the LNMs prior to radical surgery.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Xu²,

Wang

et al. 2020

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…During follow-up, a detectable PSA suggests biochemical recurrence of prostate cancer and requires prompt assessment, and may require further disease management. Further, significant advances in molecular imaging have allowed identification of biochemical recurrence at very low PSA levels 13 . Early identification of disease recurrence prior to metastatic spread allows for a wider repertoire of treatment options.…”

Section: Discussionmentioning

confidence: 99%

Primary care follow-up of radical prostatectomy patients: A regional New Zealand experience

Yassaie

McLaughlin

Perera

et al. 2016

Prostate International

View full text Add to dashboard Cite

BackgroundContemporary recommendations regarding the duration of follow-up after radical prostatectomy (RP) are highly heterogeneous. Protocol-based follow-up schemes have been implemented to facilitate the expeditious identification of patients with recurrence. The aim of this study is to assess the reliability and comfort of general practitioners (GPs) in follow-up of RP.MethodsFollowing institutional ethical approval, we performed a retrospective review in patients undergoing follow-up after RP between January 2004 and December 2010. Patient factors, disease variables, and follow-up prostate specific antigen (PSA) compliance was collected. “Noncompliant” follow-up care was defined as: patients that had not received a PSA for a 14 month period within 5 years of prostatectomy. Patient and disease-based risk factors for noncompliant follow-up were assessed. GPs were also surveyed in their follow-up practice of RP patients, to assess their familiarity in caring for these patients.ResultsIn total, 65 cases were identified that met the inclusion criteria. At 60 months of follow-up, 66% (43/65) of patients had a compliant follow-up regime. For patients with noncompliant follow-up at 60 months, median time of compliance did not differ significantly when assessing preoperative PSA, Gleason sum, extraprostatic extension, or surgical margin status. Of the GPs surveyed, 68% of GPs felt comfortable in follow-up of RP patients. Some 62% of GPs would expect the PSA to be < 0.1 and 25% of GPs would measure the PSA annually.ConclusionOur study identified that follow-up by GPs after RP is insufficient. Accordingly, there is a requirement for formal educational programs if primary care is to take a greater role in follow-up of these patients.

show abstract

“…Out of these, a small molecule inhibitor Glu-NH-CO-NH-Lys-(Axe)-[68Ga(HBED-CC)] (68Ga-PSMA-11) is being most investigated. It has shown to be of high clinical value for lymph node staging [21] and detection of local recurrence [22,23]. For BMs PSMA PET has unique distinction of being positive in bone marrow metastasis and not being positive in degenerative bone disease.…”

Section: Introductionmentioning

confidence: 99%

Is PSMA PET-CT Better than Bone Scan? When and Why

Gupta¹,

Choudhury²,

Goel³

et al. 2017

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

Prostate cancer (PCa) has a unique tropism to bone. Indeed, bone is the most frequent site of distant metastasis and cause of morbidity due to skeletal complications. 99mTc-Methylene diphosphonate (MDP) bone scintigraphy/ scan (BS) is the current standard imaging due to increase adsorption of the tracer at osteoblastic sites. However, it has limited specificity due to false positives in degenerative changes, benign causes and false negatives in bone marrow metastasis and lytic lesions. Another drawback of BS is flare response. Prostate Specific Membrane Antigen (PSMA) has been the most studies target in prostate cancer imaging in recent time due to 100-1000 time overexpression in cancer cells. 68Ga-PSMA-11, a small molecule with PSMA enzyme inhibition activity has been found promising in recurrence and lymph-node staging. In our experience of 97 staging prostate cancer patients, PSMA PET-CT showed 57.41% with pure sclerotic metastasis. Mixed (33.33%), marrow (7.14%) and lytic (2.3%) types of lesions constitute the rest and thus BS alone in these patients may leads to underestimation of bony disease burden. PSMA has not been found positive in degenerative changes however its role in response to anti-androgen needs caution due to know synergistic effect on PSMA expression. We concluded, PSMA PET-CT would have better sensitivity and specificity due to unique distinction for detecting non-sclerotic metastases. We presumed if PSMA has been performed for staging workup then there is limited role of BS except in clinical trial patient. Overall PSMA PET may become one-stop-shop for PCa workup.

show abstract

Sensitivity, specificity of 68Ga-PSMA PET in advanced prostate cancer: A systematic review and meta-analysis

Cited by 9 publications

References 0 publications

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Primary care follow-up of radical prostatectomy patients: A regional New Zealand experience

Is PSMA PET-CT Better than Bone Scan? When and Why

Contact Info

Product

Resources

About

Sensitivity, specificity of 68Ga-PSMA PET in advanced prostate cancer: A systematic review and meta-analysis

Cited by 9 publications

References 0 publications

Diagnostic Performance of 68Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Diagnostic Performance of 68Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Primary care follow-up of radical prostatectomy patients: A regional New Zealand experience

Is PSMA PET-CT Better than Bone Scan? When and Why

Contact Info

Product

Resources

About

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis

Diagnostic Performance of ⁶⁸Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-analysis